Study of Ticagrelor Alone Compared to Ticagrelor Plus Aspirin in Adults With Medically Treated Myocardial Infarction

What this Trial Is About

Researchers are evaluating the best antiplatelet treatment for patients who have had a myocardial infarction heart attack and are treated medically without revascularization procedures. This trial, called PANTHEON, focuses on whether taking ticagrelor alone can reduce bleeding events compared to the standard treatment of combining ticagrelor with aspirin for 12 months. The study aims to balance the risks of bleeding with the risks of ischemic events in this vulnerable patient group, which represents a large portion of heart attack cases in North America. Participants will be randomly assigned to receive either ticagrelor alone 90 mg twice daily plus a placebo once daily or dual antiplatelet therapy ticagrelor 90 mg twice daily combined with aspirin 80 mg once daily for one year. This phase 3 trial uses a quadruple masking method to fairly compare the treatments. The study will monitor patients from the time of randomization through 12 months to assess bleeding events and ischemic outcomes. During the trial, participants will attend scheduled study visits where researchers will evaluate bleeding events classified by the BARC system and ischemic events such as death, heart attack, stroke, or need for coronary procedures. The trial will also assess safety and effectiveness measures, including individual components of the primary outcomes. Patient adherence and clinical status will be carefully monitored throughout the 12-month treatment period.

Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone